Drug Profile
Research programme: thrombin inhibiting aptamers - ARCA biopharm/Archemix
Alternative Names: ARC-2172Latest Information Update: 04 Oct 2012
Price :
$50
*
At a glance
- Originator Archemix Corporation
- Developer ARCA biopharma Inc
- Class Nucleotide aptamers
- Mechanism of Action Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 04 Oct 2012 Discontinued - Preclinical for Thrombosis in USA (unspecified route)
- 28 Jan 2009 Nuvelo has merged with ARCA biopharma to form ARCA biopharma Inc
- 01 Feb 2008 A lead compound from this programme has entered clinical trials